Global Drugs of Abuse Testing

Drugs of Abuse Testing Comprehensive Study by Type (Psychostimulants, Narcotic, Hallucinogens, Sedatives, Others), Application (Hospitals, Diagnostics Laboratories, Forensic Laboratories, Others), Rapid Testing Device (Urine Testing, Oral Fluid Testing), Testing Type (Pain Management Testing, Criminal Justice Testing, Work Place Screening), Sample Type (Saliva, Breath, Urine, Blood, Hair and Sweat), Analyzers Type (Immunoassays, Chromatographic Devices, Breath Analyzers) Players and Region - Global Market Outlook to 2028

Drugs of Abuse Testing Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Drugs of Abuse Testing Market Scope?
Drugs of Abuse Testing is a method to detect the drugs present in a human body by the help of saliva, urine, blood, and sweat. This testing compromise of devices by which we can check or measure the intake of drugs in a human body and can be conducted at home or laboratories. According to United Nations Office on Drugs and Crime 246 million number of people of the age group from 15 to 64 used drugs and by National Survey, 9.8 million number of people across the globe suffered from mental illness due to the consumption of high drugs. Drugs that are majorly causing the addiction are cocaine, heroin, and marijuana among others. Increasing consumption of drugs by adults coupled with rising illness due to the consumption of drugs is driving the market for drugs of abuse testing.

The Drugs of Abuse Testing market study is being classified by Type (Psychostimulants, Narcotic, Hallucinogens, Sedatives and Others), by Application (Hospitals, Diagnostics Laboratories, Forensic Laboratories and Others) and major geographies with country level break-up.

Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Drugs of Abuse Testing market throughout the predicted period.

F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (United States), Drägerwerk AG & Co. KGaA (Germany), Laboratory Corporation of America Holdings (United States), Siemens Healthineers (Germany), Abbott Laboratories (United States), Danaher Corporation (Beckman Coulter, Inc.) (United States), Express Diagnostics International Inc. (United States), Shimadzu Corporation. (Japan) and Quest Diagnostics (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Psychemedics Corporation (United States), Bio-Rad Laboratories, Inc (United States) and Sonic Healthcare (Australia).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Drugs of Abuse Testing market by Type, Application and Region.

On the basis of geography, the market of Drugs of Abuse Testing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2020.

30th January 2017, The Company named Sonic Healthcare Limited acquired Medical Laboratory Bremen, a laboratory in the North-West of Germany. The acquisition was aimed at expanding the former’s presence in Germany and strengthen the company’s commitment to medical leadership in laboratory medicine.
FDA does not review drugs of abuse tests intended for employment and insurance testing provided they include a statement in their labeling that the device is intended solely for use in employment and insurance testing, and does not include test systems intended for Federal drug testing programs (e.g., programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military)

Influencing Market Trend
  • Adoption of Drug Testing At the Workplace
  • Highly Usage of Drug of Abuse Tests For Legal and Medical Purposes

Market Drivers
  • Increasing More Consumption of Drugs among Adults across Globe
  • Rising Advancements in Technology of Analyzers
  • Increasing Availability of Forbidden Drugs
  • Increase in Impact of Drug and Alcohol Abuse on Public Health

Opportunities
  • Increasing Number of Toxicological Laboratories in both Developed and Developing Countries
  • Rising Demand for Drug Abuse Testing Among Private Employers
  • Growing Emphasis on Work Place Screening Among the Urban Populations

Restraints
  • Lack of Awareness Regarding the Availability of Advanced Drug Testing Devices
  • High Prices Related To Drug Testing
  • Lack of a Global Standard Definition of a Problem Drug User

Challenges
  • Concern Related To the Inability to Detect Low-Dose Designer Drugs
  • Issue Related To Accuracy and Specificity Concerns Related To Breathalyzers


Key Target Audience
Drug of abuse testing companies, Drug of abuse testing reagent Manufacturers, Hospitals and Clinics, Diagnostics Centers, National Organizations & Government Organizations, Academic research institutes and Government institutes

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • Psychostimulants
  • Narcotic
  • Hallucinogens
  • Sedatives
  • Others
By Application
  • Hospitals
  • Diagnostics Laboratories
  • Forensic Laboratories
  • Others
By Rapid Testing Device
  • Urine Testing
  • Oral Fluid Testing

By Testing Type
  • Pain Management Testing
  • Criminal Justice Testing
  • Work Place Screening

By Sample Type
  • Saliva
  • Breath
  • Urine
  • Blood
  • Hair and Sweat

By Analyzers Type
  • Immunoassays
  • Chromatographic Devices
  • Breath Analyzers

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing More Consumption of Drugs among Adults across Globe
      • 3.2.2. Rising Advancements in Technology of Analyzers
      • 3.2.3. Increasing Availability of Forbidden Drugs
      • 3.2.4. Increase in Impact of Drug and Alcohol Abuse on Public Health
    • 3.3. Market Challenges
      • 3.3.1. Concern Related To the Inability to Detect Low-Dose Designer Drugs
      • 3.3.2. Issue Related To Accuracy and Specificity Concerns Related To Breathalyzers
    • 3.4. Market Trends
      • 3.4.1. Adoption of Drug Testing At the Workplace
      • 3.4.2. Highly Usage of Drug of Abuse Tests For Legal and Medical Purposes
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Drugs of Abuse Testing, by Type, Application, Rapid Testing Device, Testing Type, Sample Type, Analyzers Type and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Drugs of Abuse Testing (Value)
      • 5.2.1. Global Drugs of Abuse Testing by: Type (Value)
        • 5.2.1.1. Psychostimulants
        • 5.2.1.2. Narcotic
        • 5.2.1.3. Hallucinogens
        • 5.2.1.4. Sedatives
        • 5.2.1.5. Others
      • 5.2.2. Global Drugs of Abuse Testing by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Diagnostics Laboratories
        • 5.2.2.3. Forensic Laboratories
        • 5.2.2.4. Others
      • 5.2.3. Global Drugs of Abuse Testing by: Rapid Testing Device (Value)
        • 5.2.3.1. Urine Testing
        • 5.2.3.2. Oral Fluid Testing
      • 5.2.4. Global Drugs of Abuse Testing by: Testing Type (Value)
        • 5.2.4.1. Pain Management Testing
        • 5.2.4.2. Criminal Justice Testing
        • 5.2.4.3. Work Place Screening
      • 5.2.5. Global Drugs of Abuse Testing by: Sample Type (Value)
        • 5.2.5.1. Saliva
        • 5.2.5.2. Breath
        • 5.2.5.3. Urine
        • 5.2.5.4. Blood
        • 5.2.5.5. Hair and Sweat
      • 5.2.6. Global Drugs of Abuse Testing by: Analyzers Type (Value)
        • 5.2.6.1. Immunoassays
        • 5.2.6.2. Chromatographic Devices
        • 5.2.6.3. Breath Analyzers
      • 5.2.7. Global Drugs of Abuse Testing Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
    • 5.3. Global Drugs of Abuse Testing (Volume)
      • 5.3.1. Global Drugs of Abuse Testing by: Type (Volume)
        • 5.3.1.1. Psychostimulants
        • 5.3.1.2. Narcotic
        • 5.3.1.3. Hallucinogens
        • 5.3.1.4. Sedatives
        • 5.3.1.5. Others
      • 5.3.2. Global Drugs of Abuse Testing by: Application (Volume)
        • 5.3.2.1. Hospitals
        • 5.3.2.2. Diagnostics Laboratories
        • 5.3.2.3. Forensic Laboratories
        • 5.3.2.4. Others
      • 5.3.3. Global Drugs of Abuse Testing by: Rapid Testing Device (Volume)
        • 5.3.3.1. Urine Testing
        • 5.3.3.2. Oral Fluid Testing
      • 5.3.4. Global Drugs of Abuse Testing by: Testing Type (Volume)
        • 5.3.4.1. Pain Management Testing
        • 5.3.4.2. Criminal Justice Testing
        • 5.3.4.3. Work Place Screening
      • 5.3.5. Global Drugs of Abuse Testing by: Sample Type (Volume)
        • 5.3.5.1. Saliva
        • 5.3.5.2. Breath
        • 5.3.5.3. Urine
        • 5.3.5.4. Blood
        • 5.3.5.5. Hair and Sweat
      • 5.3.6. Global Drugs of Abuse Testing by: Analyzers Type (Volume)
        • 5.3.6.1. Immunoassays
        • 5.3.6.2. Chromatographic Devices
        • 5.3.6.3. Breath Analyzers
      • 5.3.7. Global Drugs of Abuse Testing Region
        • 5.3.7.1. South America
          • 5.3.7.1.1. Brazil
          • 5.3.7.1.2. Argentina
          • 5.3.7.1.3. Rest of South America
        • 5.3.7.2. Asia Pacific
          • 5.3.7.2.1. China
          • 5.3.7.2.2. Japan
          • 5.3.7.2.3. India
          • 5.3.7.2.4. South Korea
          • 5.3.7.2.5. Taiwan
          • 5.3.7.2.6. Australia
          • 5.3.7.2.7. Rest of Asia-Pacific
        • 5.3.7.3. Europe
          • 5.3.7.3.1. Germany
          • 5.3.7.3.2. France
          • 5.3.7.3.3. Italy
          • 5.3.7.3.4. United Kingdom
          • 5.3.7.3.5. Netherlands
          • 5.3.7.3.6. Rest of Europe
        • 5.3.7.4. MEA
          • 5.3.7.4.1. Middle East
          • 5.3.7.4.2. Africa
        • 5.3.7.5. North America
          • 5.3.7.5.1. United States
          • 5.3.7.5.2. Canada
          • 5.3.7.5.3. Mexico
    • 5.4. Global Drugs of Abuse Testing (Price)
      • 5.4.1. Global Drugs of Abuse Testing by: Type (Price)
  • 6. Drugs of Abuse Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Thermo Fisher Scientific Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Drägerwerk AG & Co. KGaA (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Laboratory Corporation of America Holdings (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Siemens Healthineers (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Abbott Laboratories (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Danaher Corporation (Beckman Coulter, Inc.) (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Express Diagnostics International Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Shimadzu Corporation. (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Quest Diagnostics (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Drugs of Abuse Testing Sale, by Type, Application, Rapid Testing Device, Testing Type, Sample Type, Analyzers Type and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Drugs of Abuse Testing (Value)
      • 7.2.1. Global Drugs of Abuse Testing by: Type (Value)
        • 7.2.1.1. Psychostimulants
        • 7.2.1.2. Narcotic
        • 7.2.1.3. Hallucinogens
        • 7.2.1.4. Sedatives
        • 7.2.1.5. Others
      • 7.2.2. Global Drugs of Abuse Testing by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Diagnostics Laboratories
        • 7.2.2.3. Forensic Laboratories
        • 7.2.2.4. Others
      • 7.2.3. Global Drugs of Abuse Testing by: Rapid Testing Device (Value)
        • 7.2.3.1. Urine Testing
        • 7.2.3.2. Oral Fluid Testing
      • 7.2.4. Global Drugs of Abuse Testing by: Testing Type (Value)
        • 7.2.4.1. Pain Management Testing
        • 7.2.4.2. Criminal Justice Testing
        • 7.2.4.3. Work Place Screening
      • 7.2.5. Global Drugs of Abuse Testing by: Sample Type (Value)
        • 7.2.5.1. Saliva
        • 7.2.5.2. Breath
        • 7.2.5.3. Urine
        • 7.2.5.4. Blood
        • 7.2.5.5. Hair and Sweat
      • 7.2.6. Global Drugs of Abuse Testing by: Analyzers Type (Value)
        • 7.2.6.1. Immunoassays
        • 7.2.6.2. Chromatographic Devices
        • 7.2.6.3. Breath Analyzers
      • 7.2.7. Global Drugs of Abuse Testing Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
    • 7.3. Global Drugs of Abuse Testing (Volume)
      • 7.3.1. Global Drugs of Abuse Testing by: Type (Volume)
        • 7.3.1.1. Psychostimulants
        • 7.3.1.2. Narcotic
        • 7.3.1.3. Hallucinogens
        • 7.3.1.4. Sedatives
        • 7.3.1.5. Others
      • 7.3.2. Global Drugs of Abuse Testing by: Application (Volume)
        • 7.3.2.1. Hospitals
        • 7.3.2.2. Diagnostics Laboratories
        • 7.3.2.3. Forensic Laboratories
        • 7.3.2.4. Others
      • 7.3.3. Global Drugs of Abuse Testing by: Rapid Testing Device (Volume)
        • 7.3.3.1. Urine Testing
        • 7.3.3.2. Oral Fluid Testing
      • 7.3.4. Global Drugs of Abuse Testing by: Testing Type (Volume)
        • 7.3.4.1. Pain Management Testing
        • 7.3.4.2. Criminal Justice Testing
        • 7.3.4.3. Work Place Screening
      • 7.3.5. Global Drugs of Abuse Testing by: Sample Type (Volume)
        • 7.3.5.1. Saliva
        • 7.3.5.2. Breath
        • 7.3.5.3. Urine
        • 7.3.5.4. Blood
        • 7.3.5.5. Hair and Sweat
      • 7.3.6. Global Drugs of Abuse Testing by: Analyzers Type (Volume)
        • 7.3.6.1. Immunoassays
        • 7.3.6.2. Chromatographic Devices
        • 7.3.6.3. Breath Analyzers
      • 7.3.7. Global Drugs of Abuse Testing Region
        • 7.3.7.1. South America
          • 7.3.7.1.1. Brazil
          • 7.3.7.1.2. Argentina
          • 7.3.7.1.3. Rest of South America
        • 7.3.7.2. Asia Pacific
          • 7.3.7.2.1. China
          • 7.3.7.2.2. Japan
          • 7.3.7.2.3. India
          • 7.3.7.2.4. South Korea
          • 7.3.7.2.5. Taiwan
          • 7.3.7.2.6. Australia
          • 7.3.7.2.7. Rest of Asia-Pacific
        • 7.3.7.3. Europe
          • 7.3.7.3.1. Germany
          • 7.3.7.3.2. France
          • 7.3.7.3.3. Italy
          • 7.3.7.3.4. United Kingdom
          • 7.3.7.3.5. Netherlands
          • 7.3.7.3.6. Rest of Europe
        • 7.3.7.4. MEA
          • 7.3.7.4.1. Middle East
          • 7.3.7.4.2. Africa
        • 7.3.7.5. North America
          • 7.3.7.5.1. United States
          • 7.3.7.5.2. Canada
          • 7.3.7.5.3. Mexico
    • 7.4. Global Drugs of Abuse Testing (Price)
      • 7.4.1. Global Drugs of Abuse Testing by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Drugs of Abuse Testing: by Type(USD Million)
  • Table 2. Drugs of Abuse Testing Psychostimulants , by Region USD Million (2015-2020)
  • Table 3. Drugs of Abuse Testing Narcotic , by Region USD Million (2015-2020)
  • Table 4. Drugs of Abuse Testing Hallucinogens , by Region USD Million (2015-2020)
  • Table 5. Drugs of Abuse Testing Sedatives , by Region USD Million (2015-2020)
  • Table 6. Drugs of Abuse Testing Others , by Region USD Million (2015-2020)
  • Table 7. Drugs of Abuse Testing: by Application(USD Million)
  • Table 8. Drugs of Abuse Testing Hospitals , by Region USD Million (2015-2020)
  • Table 9. Drugs of Abuse Testing Diagnostics Laboratories , by Region USD Million (2015-2020)
  • Table 10. Drugs of Abuse Testing Forensic Laboratories , by Region USD Million (2015-2020)
  • Table 11. Drugs of Abuse Testing Others , by Region USD Million (2015-2020)
  • Table 12. Drugs of Abuse Testing: by Rapid Testing Device(USD Million)
  • Table 13. Drugs of Abuse Testing Urine Testing , by Region USD Million (2015-2020)
  • Table 14. Drugs of Abuse Testing Oral Fluid Testing , by Region USD Million (2015-2020)
  • Table 15. Drugs of Abuse Testing: by Testing Type(USD Million)
  • Table 16. Drugs of Abuse Testing Pain Management Testing , by Region USD Million (2015-2020)
  • Table 17. Drugs of Abuse Testing Criminal Justice Testing , by Region USD Million (2015-2020)
  • Table 18. Drugs of Abuse Testing Work Place Screening , by Region USD Million (2015-2020)
  • Table 19. Drugs of Abuse Testing: by Sample Type(USD Million)
  • Table 20. Drugs of Abuse Testing Saliva , by Region USD Million (2015-2020)
  • Table 21. Drugs of Abuse Testing Breath , by Region USD Million (2015-2020)
  • Table 22. Drugs of Abuse Testing Urine , by Region USD Million (2015-2020)
  • Table 23. Drugs of Abuse Testing Blood , by Region USD Million (2015-2020)
  • Table 24. Drugs of Abuse Testing Hair and Sweat , by Region USD Million (2015-2020)
  • Table 25. Drugs of Abuse Testing: by Analyzers Type(USD Million)
  • Table 26. Drugs of Abuse Testing Immunoassays , by Region USD Million (2015-2020)
  • Table 27. Drugs of Abuse Testing Chromatographic Devices , by Region USD Million (2015-2020)
  • Table 28. Drugs of Abuse Testing Breath Analyzers , by Region USD Million (2015-2020)
  • Table 29. South America Drugs of Abuse Testing, by Country USD Million (2015-2020)
  • Table 30. South America Drugs of Abuse Testing, by Type USD Million (2015-2020)
  • Table 31. South America Drugs of Abuse Testing, by Application USD Million (2015-2020)
  • Table 32. South America Drugs of Abuse Testing, by Rapid Testing Device USD Million (2015-2020)
  • Table 33. South America Drugs of Abuse Testing, by Testing Type USD Million (2015-2020)
  • Table 34. South America Drugs of Abuse Testing, by Sample Type USD Million (2015-2020)
  • Table 35. South America Drugs of Abuse Testing, by Analyzers Type USD Million (2015-2020)
  • Table 36. Brazil Drugs of Abuse Testing, by Type USD Million (2015-2020)
  • Table 37. Brazil Drugs of Abuse Testing, by Application USD Million (2015-2020)
  • Table 38. Brazil Drugs of Abuse Testing, by Rapid Testing Device USD Million (2015-2020)
  • Table 39. Brazil Drugs of Abuse Testing, by Testing Type USD Million (2015-2020)
  • Table 40. Brazil Drugs of Abuse Testing, by Sample Type USD Million (2015-2020)
  • Table 41. Brazil Drugs of Abuse Testing, by Analyzers Type USD Million (2015-2020)
  • Table 42. Argentina Drugs of Abuse Testing, by Type USD Million (2015-2020)
  • Table 43. Argentina Drugs of Abuse Testing, by Application USD Million (2015-2020)
  • Table 44. Argentina Drugs of Abuse Testing, by Rapid Testing Device USD Million (2015-2020)
  • Table 45. Argentina Drugs of Abuse Testing, by Testing Type USD Million (2015-2020)
  • Table 46. Argentina Drugs of Abuse Testing, by Sample Type USD Million (2015-2020)
  • Table 47. Argentina Drugs of Abuse Testing, by Analyzers Type USD Million (2015-2020)
  • Table 48. Rest of South America Drugs of Abuse Testing, by Type USD Million (2015-2020)
  • Table 49. Rest of South America Drugs of Abuse Testing, by Application USD Million (2015-2020)
  • Table 50. Rest of South America Drugs of Abuse Testing, by Rapid Testing Device USD Million (2015-2020)
  • Table 51. Rest of South America Drugs of Abuse Testing, by Testing Type USD Million (2015-2020)
  • Table 52. Rest of South America Drugs of Abuse Testing, by Sample Type USD Million (2015-2020)
  • Table 53. Rest of South America Drugs of Abuse Testing, by Analyzers Type USD Million (2015-2020)
  • Table 54. Asia Pacific Drugs of Abuse Testing, by Country USD Million (2015-2020)
  • Table 55. Asia Pacific Drugs of Abuse Testing, by Type USD Million (2015-2020)
  • Table 56. Asia Pacific Drugs of Abuse Testing, by Application USD Million (2015-2020)
  • Table 57. Asia Pacific Drugs of Abuse Testing, by Rapid Testing Device USD Million (2015-2020)
  • Table 58. Asia Pacific Drugs of Abuse Testing, by Testing Type USD Million (2015-2020)
  • Table 59. Asia Pacific Drugs of Abuse Testing, by Sample Type USD Million (2015-2020)
  • Table 60. Asia Pacific Drugs of Abuse Testing, by Analyzers Type USD Million (2015-2020)
  • Table 61. China Drugs of Abuse Testing, by Type USD Million (2015-2020)
  • Table 62. China Drugs of Abuse Testing, by Application USD Million (2015-2020)
  • Table 63. China Drugs of Abuse Testing, by Rapid Testing Device USD Million (2015-2020)
  • Table 64. China Drugs of Abuse Testing, by Testing Type USD Million (2015-2020)
  • Table 65. China Drugs of Abuse Testing, by Sample Type USD Million (2015-2020)
  • Table 66. China Drugs of Abuse Testing, by Analyzers Type USD Million (2015-2020)
  • Table 67. Japan Drugs of Abuse Testing, by Type USD Million (2015-2020)
  • Table 68. Japan Drugs of Abuse Testing, by Application USD Million (2015-2020)
  • Table 69. Japan Drugs of Abuse Testing, by Rapid Testing Device USD Million (2015-2020)
  • Table 70. Japan Drugs of Abuse Testing, by Testing Type USD Million (2015-2020)
  • Table 71. Japan Drugs of Abuse Testing, by Sample Type USD Million (2015-2020)
  • Table 72. Japan Drugs of Abuse Testing, by Analyzers Type USD Million (2015-2020)
  • Table 73. India Drugs of Abuse Testing, by Type USD Million (2015-2020)
  • Table 74. India Drugs of Abuse Testing, by Application USD Million (2015-2020)
  • Table 75. India Drugs of Abuse Testing, by Rapid Testing Device USD Million (2015-2020)
  • Table 76. India Drugs of Abuse Testing, by Testing Type USD Million (2015-2020)
  • Table 77. India Drugs of Abuse Testing, by Sample Type USD Million (2015-2020)
  • Table 78. India Drugs of Abuse Testing, by Analyzers Type USD Million (2015-2020)
  • Table 79. South Korea Drugs of Abuse Testing, by Type USD Million (2015-2020)
  • Table 80. South Korea Drugs of Abuse Testing, by Application USD Million (2015-2020)
  • Table 81. South Korea Drugs of Abuse Testing, by Rapid Testing Device USD Million (2015-2020)
  • Table 82. South Korea Drugs of Abuse Testing, by Testing Type USD Million (2015-2020)
  • Table 83. South Korea Drugs of Abuse Testing, by Sample Type USD Million (2015-2020)
  • Table 84. South Korea Drugs of Abuse Testing, by Analyzers Type USD Million (2015-2020)
  • Table 85. Taiwan Drugs of Abuse Testing, by Type USD Million (2015-2020)
  • Table 86. Taiwan Drugs of Abuse Testing, by Application USD Million (2015-2020)
  • Table 87. Taiwan Drugs of Abuse Testing, by Rapid Testing Device USD Million (2015-2020)
  • Table 88. Taiwan Drugs of Abuse Testing, by Testing Type USD Million (2015-2020)
  • Table 89. Taiwan Drugs of Abuse Testing, by Sample Type USD Million (2015-2020)
  • Table 90. Taiwan Drugs of Abuse Testing, by Analyzers Type USD Million (2015-2020)
  • Table 91. Australia Drugs of Abuse Testing, by Type USD Million (2015-2020)
  • Table 92. Australia Drugs of Abuse Testing, by Application USD Million (2015-2020)
  • Table 93. Australia Drugs of Abuse Testing, by Rapid Testing Device USD Million (2015-2020)
  • Table 94. Australia Drugs of Abuse Testing, by Testing Type USD Million (2015-2020)
  • Table 95. Australia Drugs of Abuse Testing, by Sample Type USD Million (2015-2020)
  • Table 96. Australia Drugs of Abuse Testing, by Analyzers Type USD Million (2015-2020)
  • Table 97. Rest of Asia-Pacific Drugs of Abuse Testing, by Type USD Million (2015-2020)
  • Table 98. Rest of Asia-Pacific Drugs of Abuse Testing, by Application USD Million (2015-2020)
  • Table 99. Rest of Asia-Pacific Drugs of Abuse Testing, by Rapid Testing Device USD Million (2015-2020)
  • Table 100. Rest of Asia-Pacific Drugs of Abuse Testing, by Testing Type USD Million (2015-2020)
  • Table 101. Rest of Asia-Pacific Drugs of Abuse Testing, by Sample Type USD Million (2015-2020)
  • Table 102. Rest of Asia-Pacific Drugs of Abuse Testing, by Analyzers Type USD Million (2015-2020)
  • Table 103. Europe Drugs of Abuse Testing, by Country USD Million (2015-2020)
  • Table 104. Europe Drugs of Abuse Testing, by Type USD Million (2015-2020)
  • Table 105. Europe Drugs of Abuse Testing, by Application USD Million (2015-2020)
  • Table 106. Europe Drugs of Abuse Testing, by Rapid Testing Device USD Million (2015-2020)
  • Table 107. Europe Drugs of Abuse Testing, by Testing Type USD Million (2015-2020)
  • Table 108. Europe Drugs of Abuse Testing, by Sample Type USD Million (2015-2020)
  • Table 109. Europe Drugs of Abuse Testing, by Analyzers Type USD Million (2015-2020)
  • Table 110. Germany Drugs of Abuse Testing, by Type USD Million (2015-2020)
  • Table 111. Germany Drugs of Abuse Testing, by Application USD Million (2015-2020)
  • Table 112. Germany Drugs of Abuse Testing, by Rapid Testing Device USD Million (2015-2020)
  • Table 113. Germany Drugs of Abuse Testing, by Testing Type USD Million (2015-2020)
  • Table 114. Germany Drugs of Abuse Testing, by Sample Type USD Million (2015-2020)
  • Table 115. Germany Drugs of Abuse Testing, by Analyzers Type USD Million (2015-2020)
  • Table 116. France Drugs of Abuse Testing, by Type USD Million (2015-2020)
  • Table 117. France Drugs of Abuse Testing, by Application USD Million (2015-2020)
  • Table 118. France Drugs of Abuse Testing, by Rapid Testing Device USD Million (2015-2020)
  • Table 119. France Drugs of Abuse Testing, by Testing Type USD Million (2015-2020)
  • Table 120. France Drugs of Abuse Testing, by Sample Type USD Million (2015-2020)
  • Table 121. France Drugs of Abuse Testing, by Analyzers Type USD Million (2015-2020)
  • Table 122. Italy Drugs of Abuse Testing, by Type USD Million (2015-2020)
  • Table 123. Italy Drugs of Abuse Testing, by Application USD Million (2015-2020)
  • Table 124. Italy Drugs of Abuse Testing, by Rapid Testing Device USD Million (2015-2020)
  • Table 125. Italy Drugs of Abuse Testing, by Testing Type USD Million (2015-2020)
  • Table 126. Italy Drugs of Abuse Testing, by Sample Type USD Million (2015-2020)
  • Table 127. Italy Drugs of Abuse Testing, by Analyzers Type USD Million (2015-2020)
  • Table 128. United Kingdom Drugs of Abuse Testing, by Type USD Million (2015-2020)
  • Table 129. United Kingdom Drugs of Abuse Testing, by Application USD Million (2015-2020)
  • Table 130. United Kingdom Drugs of Abuse Testing, by Rapid Testing Device USD Million (2015-2020)
  • Table 131. United Kingdom Drugs of Abuse Testing, by Testing Type USD Million (2015-2020)
  • Table 132. United Kingdom Drugs of Abuse Testing, by Sample Type USD Million (2015-2020)
  • Table 133. United Kingdom Drugs of Abuse Testing, by Analyzers Type USD Million (2015-2020)
  • Table 134. Netherlands Drugs of Abuse Testing, by Type USD Million (2015-2020)
  • Table 135. Netherlands Drugs of Abuse Testing, by Application USD Million (2015-2020)
  • Table 136. Netherlands Drugs of Abuse Testing, by Rapid Testing Device USD Million (2015-2020)
  • Table 137. Netherlands Drugs of Abuse Testing, by Testing Type USD Million (2015-2020)
  • Table 138. Netherlands Drugs of Abuse Testing, by Sample Type USD Million (2015-2020)
  • Table 139. Netherlands Drugs of Abuse Testing, by Analyzers Type USD Million (2015-2020)
  • Table 140. Rest of Europe Drugs of Abuse Testing, by Type USD Million (2015-2020)
  • Table 141. Rest of Europe Drugs of Abuse Testing, by Application USD Million (2015-2020)
  • Table 142. Rest of Europe Drugs of Abuse Testing, by Rapid Testing Device USD Million (2015-2020)
  • Table 143. Rest of Europe Drugs of Abuse Testing, by Testing Type USD Million (2015-2020)
  • Table 144. Rest of Europe Drugs of Abuse Testing, by Sample Type USD Million (2015-2020)
  • Table 145. Rest of Europe Drugs of Abuse Testing, by Analyzers Type USD Million (2015-2020)
  • Table 146. MEA Drugs of Abuse Testing, by Country USD Million (2015-2020)
  • Table 147. MEA Drugs of Abuse Testing, by Type USD Million (2015-2020)
  • Table 148. MEA Drugs of Abuse Testing, by Application USD Million (2015-2020)
  • Table 149. MEA Drugs of Abuse Testing, by Rapid Testing Device USD Million (2015-2020)
  • Table 150. MEA Drugs of Abuse Testing, by Testing Type USD Million (2015-2020)
  • Table 151. MEA Drugs of Abuse Testing, by Sample Type USD Million (2015-2020)
  • Table 152. MEA Drugs of Abuse Testing, by Analyzers Type USD Million (2015-2020)
  • Table 153. Middle East Drugs of Abuse Testing, by Type USD Million (2015-2020)
  • Table 154. Middle East Drugs of Abuse Testing, by Application USD Million (2015-2020)
  • Table 155. Middle East Drugs of Abuse Testing, by Rapid Testing Device USD Million (2015-2020)
  • Table 156. Middle East Drugs of Abuse Testing, by Testing Type USD Million (2015-2020)
  • Table 157. Middle East Drugs of Abuse Testing, by Sample Type USD Million (2015-2020)
  • Table 158. Middle East Drugs of Abuse Testing, by Analyzers Type USD Million (2015-2020)
  • Table 159. Africa Drugs of Abuse Testing, by Type USD Million (2015-2020)
  • Table 160. Africa Drugs of Abuse Testing, by Application USD Million (2015-2020)
  • Table 161. Africa Drugs of Abuse Testing, by Rapid Testing Device USD Million (2015-2020)
  • Table 162. Africa Drugs of Abuse Testing, by Testing Type USD Million (2015-2020)
  • Table 163. Africa Drugs of Abuse Testing, by Sample Type USD Million (2015-2020)
  • Table 164. Africa Drugs of Abuse Testing, by Analyzers Type USD Million (2015-2020)
  • Table 165. North America Drugs of Abuse Testing, by Country USD Million (2015-2020)
  • Table 166. North America Drugs of Abuse Testing, by Type USD Million (2015-2020)
  • Table 167. North America Drugs of Abuse Testing, by Application USD Million (2015-2020)
  • Table 168. North America Drugs of Abuse Testing, by Rapid Testing Device USD Million (2015-2020)
  • Table 169. North America Drugs of Abuse Testing, by Testing Type USD Million (2015-2020)
  • Table 170. North America Drugs of Abuse Testing, by Sample Type USD Million (2015-2020)
  • Table 171. North America Drugs of Abuse Testing, by Analyzers Type USD Million (2015-2020)
  • Table 172. United States Drugs of Abuse Testing, by Type USD Million (2015-2020)
  • Table 173. United States Drugs of Abuse Testing, by Application USD Million (2015-2020)
  • Table 174. United States Drugs of Abuse Testing, by Rapid Testing Device USD Million (2015-2020)
  • Table 175. United States Drugs of Abuse Testing, by Testing Type USD Million (2015-2020)
  • Table 176. United States Drugs of Abuse Testing, by Sample Type USD Million (2015-2020)
  • Table 177. United States Drugs of Abuse Testing, by Analyzers Type USD Million (2015-2020)
  • Table 178. Canada Drugs of Abuse Testing, by Type USD Million (2015-2020)
  • Table 179. Canada Drugs of Abuse Testing, by Application USD Million (2015-2020)
  • Table 180. Canada Drugs of Abuse Testing, by Rapid Testing Device USD Million (2015-2020)
  • Table 181. Canada Drugs of Abuse Testing, by Testing Type USD Million (2015-2020)
  • Table 182. Canada Drugs of Abuse Testing, by Sample Type USD Million (2015-2020)
  • Table 183. Canada Drugs of Abuse Testing, by Analyzers Type USD Million (2015-2020)
  • Table 184. Mexico Drugs of Abuse Testing, by Type USD Million (2015-2020)
  • Table 185. Mexico Drugs of Abuse Testing, by Application USD Million (2015-2020)
  • Table 186. Mexico Drugs of Abuse Testing, by Rapid Testing Device USD Million (2015-2020)
  • Table 187. Mexico Drugs of Abuse Testing, by Testing Type USD Million (2015-2020)
  • Table 188. Mexico Drugs of Abuse Testing, by Sample Type USD Million (2015-2020)
  • Table 189. Mexico Drugs of Abuse Testing, by Analyzers Type USD Million (2015-2020)
  • Table 190. Drugs of Abuse Testing Sales: by Type(Unit)
  • Table 191. Drugs of Abuse Testing Sales Psychostimulants , by Region Unit (2015-2020)
  • Table 192. Drugs of Abuse Testing Sales Narcotic , by Region Unit (2015-2020)
  • Table 193. Drugs of Abuse Testing Sales Hallucinogens , by Region Unit (2015-2020)
  • Table 194. Drugs of Abuse Testing Sales Sedatives , by Region Unit (2015-2020)
  • Table 195. Drugs of Abuse Testing Sales Others , by Region Unit (2015-2020)
  • Table 196. Drugs of Abuse Testing Sales: by Application(Unit)
  • Table 197. Drugs of Abuse Testing Sales Hospitals , by Region Unit (2015-2020)
  • Table 198. Drugs of Abuse Testing Sales Diagnostics Laboratories , by Region Unit (2015-2020)
  • Table 199. Drugs of Abuse Testing Sales Forensic Laboratories , by Region Unit (2015-2020)
  • Table 200. Drugs of Abuse Testing Sales Others , by Region Unit (2015-2020)
  • Table 201. Drugs of Abuse Testing Sales: by Rapid Testing Device(Unit)
  • Table 202. Drugs of Abuse Testing Sales Urine Testing , by Region Unit (2015-2020)
  • Table 203. Drugs of Abuse Testing Sales Oral Fluid Testing , by Region Unit (2015-2020)
  • Table 204. Drugs of Abuse Testing Sales: by Testing Type(Unit)
  • Table 205. Drugs of Abuse Testing Sales Pain Management Testing , by Region Unit (2015-2020)
  • Table 206. Drugs of Abuse Testing Sales Criminal Justice Testing , by Region Unit (2015-2020)
  • Table 207. Drugs of Abuse Testing Sales Work Place Screening , by Region Unit (2015-2020)
  • Table 208. Drugs of Abuse Testing Sales: by Sample Type(Unit)
  • Table 209. Drugs of Abuse Testing Sales Saliva , by Region Unit (2015-2020)
  • Table 210. Drugs of Abuse Testing Sales Breath , by Region Unit (2015-2020)
  • Table 211. Drugs of Abuse Testing Sales Urine , by Region Unit (2015-2020)
  • Table 212. Drugs of Abuse Testing Sales Blood , by Region Unit (2015-2020)
  • Table 213. Drugs of Abuse Testing Sales Hair and Sweat , by Region Unit (2015-2020)
  • Table 214. Drugs of Abuse Testing Sales: by Analyzers Type(Unit)
  • Table 215. Drugs of Abuse Testing Sales Immunoassays , by Region Unit (2015-2020)
  • Table 216. Drugs of Abuse Testing Sales Chromatographic Devices , by Region Unit (2015-2020)
  • Table 217. Drugs of Abuse Testing Sales Breath Analyzers , by Region Unit (2015-2020)
  • Table 218. South America Drugs of Abuse Testing Sales, by Country Unit (2015-2020)
  • Table 219. South America Drugs of Abuse Testing Sales, by Type Unit (2015-2020)
  • Table 220. South America Drugs of Abuse Testing Sales, by Application Unit (2015-2020)
  • Table 221. South America Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2015-2020)
  • Table 222. South America Drugs of Abuse Testing Sales, by Testing Type Unit (2015-2020)
  • Table 223. South America Drugs of Abuse Testing Sales, by Sample Type Unit (2015-2020)
  • Table 224. South America Drugs of Abuse Testing Sales, by Analyzers Type Unit (2015-2020)
  • Table 225. Brazil Drugs of Abuse Testing Sales, by Type Unit (2015-2020)
  • Table 226. Brazil Drugs of Abuse Testing Sales, by Application Unit (2015-2020)
  • Table 227. Brazil Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2015-2020)
  • Table 228. Brazil Drugs of Abuse Testing Sales, by Testing Type Unit (2015-2020)
  • Table 229. Brazil Drugs of Abuse Testing Sales, by Sample Type Unit (2015-2020)
  • Table 230. Brazil Drugs of Abuse Testing Sales, by Analyzers Type Unit (2015-2020)
  • Table 231. Argentina Drugs of Abuse Testing Sales, by Type Unit (2015-2020)
  • Table 232. Argentina Drugs of Abuse Testing Sales, by Application Unit (2015-2020)
  • Table 233. Argentina Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2015-2020)
  • Table 234. Argentina Drugs of Abuse Testing Sales, by Testing Type Unit (2015-2020)
  • Table 235. Argentina Drugs of Abuse Testing Sales, by Sample Type Unit (2015-2020)
  • Table 236. Argentina Drugs of Abuse Testing Sales, by Analyzers Type Unit (2015-2020)
  • Table 237. Rest of South America Drugs of Abuse Testing Sales, by Type Unit (2015-2020)
  • Table 238. Rest of South America Drugs of Abuse Testing Sales, by Application Unit (2015-2020)
  • Table 239. Rest of South America Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2015-2020)
  • Table 240. Rest of South America Drugs of Abuse Testing Sales, by Testing Type Unit (2015-2020)
  • Table 241. Rest of South America Drugs of Abuse Testing Sales, by Sample Type Unit (2015-2020)
  • Table 242. Rest of South America Drugs of Abuse Testing Sales, by Analyzers Type Unit (2015-2020)
  • Table 243. Asia Pacific Drugs of Abuse Testing Sales, by Country Unit (2015-2020)
  • Table 244. Asia Pacific Drugs of Abuse Testing Sales, by Type Unit (2015-2020)
  • Table 245. Asia Pacific Drugs of Abuse Testing Sales, by Application Unit (2015-2020)
  • Table 246. Asia Pacific Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2015-2020)
  • Table 247. Asia Pacific Drugs of Abuse Testing Sales, by Testing Type Unit (2015-2020)
  • Table 248. Asia Pacific Drugs of Abuse Testing Sales, by Sample Type Unit (2015-2020)
  • Table 249. Asia Pacific Drugs of Abuse Testing Sales, by Analyzers Type Unit (2015-2020)
  • Table 250. China Drugs of Abuse Testing Sales, by Type Unit (2015-2020)
  • Table 251. China Drugs of Abuse Testing Sales, by Application Unit (2015-2020)
  • Table 252. China Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2015-2020)
  • Table 253. China Drugs of Abuse Testing Sales, by Testing Type Unit (2015-2020)
  • Table 254. China Drugs of Abuse Testing Sales, by Sample Type Unit (2015-2020)
  • Table 255. China Drugs of Abuse Testing Sales, by Analyzers Type Unit (2015-2020)
  • Table 256. Japan Drugs of Abuse Testing Sales, by Type Unit (2015-2020)
  • Table 257. Japan Drugs of Abuse Testing Sales, by Application Unit (2015-2020)
  • Table 258. Japan Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2015-2020)
  • Table 259. Japan Drugs of Abuse Testing Sales, by Testing Type Unit (2015-2020)
  • Table 260. Japan Drugs of Abuse Testing Sales, by Sample Type Unit (2015-2020)
  • Table 261. Japan Drugs of Abuse Testing Sales, by Analyzers Type Unit (2015-2020)
  • Table 262. India Drugs of Abuse Testing Sales, by Type Unit (2015-2020)
  • Table 263. India Drugs of Abuse Testing Sales, by Application Unit (2015-2020)
  • Table 264. India Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2015-2020)
  • Table 265. India Drugs of Abuse Testing Sales, by Testing Type Unit (2015-2020)
  • Table 266. India Drugs of Abuse Testing Sales, by Sample Type Unit (2015-2020)
  • Table 267. India Drugs of Abuse Testing Sales, by Analyzers Type Unit (2015-2020)
  • Table 268. South Korea Drugs of Abuse Testing Sales, by Type Unit (2015-2020)
  • Table 269. South Korea Drugs of Abuse Testing Sales, by Application Unit (2015-2020)
  • Table 270. South Korea Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2015-2020)
  • Table 271. South Korea Drugs of Abuse Testing Sales, by Testing Type Unit (2015-2020)
  • Table 272. South Korea Drugs of Abuse Testing Sales, by Sample Type Unit (2015-2020)
  • Table 273. South Korea Drugs of Abuse Testing Sales, by Analyzers Type Unit (2015-2020)
  • Table 274. Taiwan Drugs of Abuse Testing Sales, by Type Unit (2015-2020)
  • Table 275. Taiwan Drugs of Abuse Testing Sales, by Application Unit (2015-2020)
  • Table 276. Taiwan Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2015-2020)
  • Table 277. Taiwan Drugs of Abuse Testing Sales, by Testing Type Unit (2015-2020)
  • Table 278. Taiwan Drugs of Abuse Testing Sales, by Sample Type Unit (2015-2020)
  • Table 279. Taiwan Drugs of Abuse Testing Sales, by Analyzers Type Unit (2015-2020)
  • Table 280. Australia Drugs of Abuse Testing Sales, by Type Unit (2015-2020)
  • Table 281. Australia Drugs of Abuse Testing Sales, by Application Unit (2015-2020)
  • Table 282. Australia Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2015-2020)
  • Table 283. Australia Drugs of Abuse Testing Sales, by Testing Type Unit (2015-2020)
  • Table 284. Australia Drugs of Abuse Testing Sales, by Sample Type Unit (2015-2020)
  • Table 285. Australia Drugs of Abuse Testing Sales, by Analyzers Type Unit (2015-2020)
  • Table 286. Rest of Asia-Pacific Drugs of Abuse Testing Sales, by Type Unit (2015-2020)
  • Table 287. Rest of Asia-Pacific Drugs of Abuse Testing Sales, by Application Unit (2015-2020)
  • Table 288. Rest of Asia-Pacific Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2015-2020)
  • Table 289. Rest of Asia-Pacific Drugs of Abuse Testing Sales, by Testing Type Unit (2015-2020)
  • Table 290. Rest of Asia-Pacific Drugs of Abuse Testing Sales, by Sample Type Unit (2015-2020)
  • Table 291. Rest of Asia-Pacific Drugs of Abuse Testing Sales, by Analyzers Type Unit (2015-2020)
  • Table 292. Europe Drugs of Abuse Testing Sales, by Country Unit (2015-2020)
  • Table 293. Europe Drugs of Abuse Testing Sales, by Type Unit (2015-2020)
  • Table 294. Europe Drugs of Abuse Testing Sales, by Application Unit (2015-2020)
  • Table 295. Europe Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2015-2020)
  • Table 296. Europe Drugs of Abuse Testing Sales, by Testing Type Unit (2015-2020)
  • Table 297. Europe Drugs of Abuse Testing Sales, by Sample Type Unit (2015-2020)
  • Table 298. Europe Drugs of Abuse Testing Sales, by Analyzers Type Unit (2015-2020)
  • Table 299. Germany Drugs of Abuse Testing Sales, by Type Unit (2015-2020)
  • Table 300. Germany Drugs of Abuse Testing Sales, by Application Unit (2015-2020)
  • Table 301. Germany Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2015-2020)
  • Table 302. Germany Drugs of Abuse Testing Sales, by Testing Type Unit (2015-2020)
  • Table 303. Germany Drugs of Abuse Testing Sales, by Sample Type Unit (2015-2020)
  • Table 304. Germany Drugs of Abuse Testing Sales, by Analyzers Type Unit (2015-2020)
  • Table 305. France Drugs of Abuse Testing Sales, by Type Unit (2015-2020)
  • Table 306. France Drugs of Abuse Testing Sales, by Application Unit (2015-2020)
  • Table 307. France Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2015-2020)
  • Table 308. France Drugs of Abuse Testing Sales, by Testing Type Unit (2015-2020)
  • Table 309. France Drugs of Abuse Testing Sales, by Sample Type Unit (2015-2020)
  • Table 310. France Drugs of Abuse Testing Sales, by Analyzers Type Unit (2015-2020)
  • Table 311. Italy Drugs of Abuse Testing Sales, by Type Unit (2015-2020)
  • Table 312. Italy Drugs of Abuse Testing Sales, by Application Unit (2015-2020)
  • Table 313. Italy Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2015-2020)
  • Table 314. Italy Drugs of Abuse Testing Sales, by Testing Type Unit (2015-2020)
  • Table 315. Italy Drugs of Abuse Testing Sales, by Sample Type Unit (2015-2020)
  • Table 316. Italy Drugs of Abuse Testing Sales, by Analyzers Type Unit (2015-2020)
  • Table 317. United Kingdom Drugs of Abuse Testing Sales, by Type Unit (2015-2020)
  • Table 318. United Kingdom Drugs of Abuse Testing Sales, by Application Unit (2015-2020)
  • Table 319. United Kingdom Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2015-2020)
  • Table 320. United Kingdom Drugs of Abuse Testing Sales, by Testing Type Unit (2015-2020)
  • Table 321. United Kingdom Drugs of Abuse Testing Sales, by Sample Type Unit (2015-2020)
  • Table 322. United Kingdom Drugs of Abuse Testing Sales, by Analyzers Type Unit (2015-2020)
  • Table 323. Netherlands Drugs of Abuse Testing Sales, by Type Unit (2015-2020)
  • Table 324. Netherlands Drugs of Abuse Testing Sales, by Application Unit (2015-2020)
  • Table 325. Netherlands Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2015-2020)
  • Table 326. Netherlands Drugs of Abuse Testing Sales, by Testing Type Unit (2015-2020)
  • Table 327. Netherlands Drugs of Abuse Testing Sales, by Sample Type Unit (2015-2020)
  • Table 328. Netherlands Drugs of Abuse Testing Sales, by Analyzers Type Unit (2015-2020)
  • Table 329. Rest of Europe Drugs of Abuse Testing Sales, by Type Unit (2015-2020)
  • Table 330. Rest of Europe Drugs of Abuse Testing Sales, by Application Unit (2015-2020)
  • Table 331. Rest of Europe Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2015-2020)
  • Table 332. Rest of Europe Drugs of Abuse Testing Sales, by Testing Type Unit (2015-2020)
  • Table 333. Rest of Europe Drugs of Abuse Testing Sales, by Sample Type Unit (2015-2020)
  • Table 334. Rest of Europe Drugs of Abuse Testing Sales, by Analyzers Type Unit (2015-2020)
  • Table 335. MEA Drugs of Abuse Testing Sales, by Country Unit (2015-2020)
  • Table 336. MEA Drugs of Abuse Testing Sales, by Type Unit (2015-2020)
  • Table 337. MEA Drugs of Abuse Testing Sales, by Application Unit (2015-2020)
  • Table 338. MEA Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2015-2020)
  • Table 339. MEA Drugs of Abuse Testing Sales, by Testing Type Unit (2015-2020)
  • Table 340. MEA Drugs of Abuse Testing Sales, by Sample Type Unit (2015-2020)
  • Table 341. MEA Drugs of Abuse Testing Sales, by Analyzers Type Unit (2015-2020)
  • Table 342. Middle East Drugs of Abuse Testing Sales, by Type Unit (2015-2020)
  • Table 343. Middle East Drugs of Abuse Testing Sales, by Application Unit (2015-2020)
  • Table 344. Middle East Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2015-2020)
  • Table 345. Middle East Drugs of Abuse Testing Sales, by Testing Type Unit (2015-2020)
  • Table 346. Middle East Drugs of Abuse Testing Sales, by Sample Type Unit (2015-2020)
  • Table 347. Middle East Drugs of Abuse Testing Sales, by Analyzers Type Unit (2015-2020)
  • Table 348. Africa Drugs of Abuse Testing Sales, by Type Unit (2015-2020)
  • Table 349. Africa Drugs of Abuse Testing Sales, by Application Unit (2015-2020)
  • Table 350. Africa Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2015-2020)
  • Table 351. Africa Drugs of Abuse Testing Sales, by Testing Type Unit (2015-2020)
  • Table 352. Africa Drugs of Abuse Testing Sales, by Sample Type Unit (2015-2020)
  • Table 353. Africa Drugs of Abuse Testing Sales, by Analyzers Type Unit (2015-2020)
  • Table 354. North America Drugs of Abuse Testing Sales, by Country Unit (2015-2020)
  • Table 355. North America Drugs of Abuse Testing Sales, by Type Unit (2015-2020)
  • Table 356. North America Drugs of Abuse Testing Sales, by Application Unit (2015-2020)
  • Table 357. North America Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2015-2020)
  • Table 358. North America Drugs of Abuse Testing Sales, by Testing Type Unit (2015-2020)
  • Table 359. North America Drugs of Abuse Testing Sales, by Sample Type Unit (2015-2020)
  • Table 360. North America Drugs of Abuse Testing Sales, by Analyzers Type Unit (2015-2020)
  • Table 361. United States Drugs of Abuse Testing Sales, by Type Unit (2015-2020)
  • Table 362. United States Drugs of Abuse Testing Sales, by Application Unit (2015-2020)
  • Table 363. United States Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2015-2020)
  • Table 364. United States Drugs of Abuse Testing Sales, by Testing Type Unit (2015-2020)
  • Table 365. United States Drugs of Abuse Testing Sales, by Sample Type Unit (2015-2020)
  • Table 366. United States Drugs of Abuse Testing Sales, by Analyzers Type Unit (2015-2020)
  • Table 367. Canada Drugs of Abuse Testing Sales, by Type Unit (2015-2020)
  • Table 368. Canada Drugs of Abuse Testing Sales, by Application Unit (2015-2020)
  • Table 369. Canada Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2015-2020)
  • Table 370. Canada Drugs of Abuse Testing Sales, by Testing Type Unit (2015-2020)
  • Table 371. Canada Drugs of Abuse Testing Sales, by Sample Type Unit (2015-2020)
  • Table 372. Canada Drugs of Abuse Testing Sales, by Analyzers Type Unit (2015-2020)
  • Table 373. Mexico Drugs of Abuse Testing Sales, by Type Unit (2015-2020)
  • Table 374. Mexico Drugs of Abuse Testing Sales, by Application Unit (2015-2020)
  • Table 375. Mexico Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2015-2020)
  • Table 376. Mexico Drugs of Abuse Testing Sales, by Testing Type Unit (2015-2020)
  • Table 377. Mexico Drugs of Abuse Testing Sales, by Sample Type Unit (2015-2020)
  • Table 378. Mexico Drugs of Abuse Testing Sales, by Analyzers Type Unit (2015-2020)
  • Table 379. Drugs of Abuse Testing: by Type(USD/Units)
  • Table 380. Company Basic Information, Sales Area and Its Competitors
  • Table 381. Company Basic Information, Sales Area and Its Competitors
  • Table 382. Company Basic Information, Sales Area and Its Competitors
  • Table 383. Company Basic Information, Sales Area and Its Competitors
  • Table 384. Company Basic Information, Sales Area and Its Competitors
  • Table 385. Company Basic Information, Sales Area and Its Competitors
  • Table 386. Company Basic Information, Sales Area and Its Competitors
  • Table 387. Company Basic Information, Sales Area and Its Competitors
  • Table 388. Company Basic Information, Sales Area and Its Competitors
  • Table 389. Company Basic Information, Sales Area and Its Competitors
  • Table 390. Drugs of Abuse Testing: by Type(USD Million)
  • Table 391. Drugs of Abuse Testing Psychostimulants , by Region USD Million (2021-2026)
  • Table 392. Drugs of Abuse Testing Narcotic , by Region USD Million (2021-2026)
  • Table 393. Drugs of Abuse Testing Hallucinogens , by Region USD Million (2021-2026)
  • Table 394. Drugs of Abuse Testing Sedatives , by Region USD Million (2021-2026)
  • Table 395. Drugs of Abuse Testing Others , by Region USD Million (2021-2026)
  • Table 396. Drugs of Abuse Testing: by Application(USD Million)
  • Table 397. Drugs of Abuse Testing Hospitals , by Region USD Million (2021-2026)
  • Table 398. Drugs of Abuse Testing Diagnostics Laboratories , by Region USD Million (2021-2026)
  • Table 399. Drugs of Abuse Testing Forensic Laboratories , by Region USD Million (2021-2026)
  • Table 400. Drugs of Abuse Testing Others , by Region USD Million (2021-2026)
  • Table 401. Drugs of Abuse Testing: by Rapid Testing Device(USD Million)
  • Table 402. Drugs of Abuse Testing Urine Testing , by Region USD Million (2021-2026)
  • Table 403. Drugs of Abuse Testing Oral Fluid Testing , by Region USD Million (2021-2026)
  • Table 404. Drugs of Abuse Testing: by Testing Type(USD Million)
  • Table 405. Drugs of Abuse Testing Pain Management Testing , by Region USD Million (2021-2026)
  • Table 406. Drugs of Abuse Testing Criminal Justice Testing , by Region USD Million (2021-2026)
  • Table 407. Drugs of Abuse Testing Work Place Screening , by Region USD Million (2021-2026)
  • Table 408. Drugs of Abuse Testing: by Sample Type(USD Million)
  • Table 409. Drugs of Abuse Testing Saliva , by Region USD Million (2021-2026)
  • Table 410. Drugs of Abuse Testing Breath , by Region USD Million (2021-2026)
  • Table 411. Drugs of Abuse Testing Urine , by Region USD Million (2021-2026)
  • Table 412. Drugs of Abuse Testing Blood , by Region USD Million (2021-2026)
  • Table 413. Drugs of Abuse Testing Hair and Sweat , by Region USD Million (2021-2026)
  • Table 414. Drugs of Abuse Testing: by Analyzers Type(USD Million)
  • Table 415. Drugs of Abuse Testing Immunoassays , by Region USD Million (2021-2026)
  • Table 416. Drugs of Abuse Testing Chromatographic Devices , by Region USD Million (2021-2026)
  • Table 417. Drugs of Abuse Testing Breath Analyzers , by Region USD Million (2021-2026)
  • Table 418. South America Drugs of Abuse Testing, by Country USD Million (2021-2026)
  • Table 419. South America Drugs of Abuse Testing, by Type USD Million (2021-2026)
  • Table 420. South America Drugs of Abuse Testing, by Application USD Million (2021-2026)
  • Table 421. South America Drugs of Abuse Testing, by Rapid Testing Device USD Million (2021-2026)
  • Table 422. South America Drugs of Abuse Testing, by Testing Type USD Million (2021-2026)
  • Table 423. South America Drugs of Abuse Testing, by Sample Type USD Million (2021-2026)
  • Table 424. South America Drugs of Abuse Testing, by Analyzers Type USD Million (2021-2026)
  • Table 425. Brazil Drugs of Abuse Testing, by Type USD Million (2021-2026)
  • Table 426. Brazil Drugs of Abuse Testing, by Application USD Million (2021-2026)
  • Table 427. Brazil Drugs of Abuse Testing, by Rapid Testing Device USD Million (2021-2026)
  • Table 428. Brazil Drugs of Abuse Testing, by Testing Type USD Million (2021-2026)
  • Table 429. Brazil Drugs of Abuse Testing, by Sample Type USD Million (2021-2026)
  • Table 430. Brazil Drugs of Abuse Testing, by Analyzers Type USD Million (2021-2026)
  • Table 431. Argentina Drugs of Abuse Testing, by Type USD Million (2021-2026)
  • Table 432. Argentina Drugs of Abuse Testing, by Application USD Million (2021-2026)
  • Table 433. Argentina Drugs of Abuse Testing, by Rapid Testing Device USD Million (2021-2026)
  • Table 434. Argentina Drugs of Abuse Testing, by Testing Type USD Million (2021-2026)
  • Table 435. Argentina Drugs of Abuse Testing, by Sample Type USD Million (2021-2026)
  • Table 436. Argentina Drugs of Abuse Testing, by Analyzers Type USD Million (2021-2026)
  • Table 437. Rest of South America Drugs of Abuse Testing, by Type USD Million (2021-2026)
  • Table 438. Rest of South America Drugs of Abuse Testing, by Application USD Million (2021-2026)
  • Table 439. Rest of South America Drugs of Abuse Testing, by Rapid Testing Device USD Million (2021-2026)
  • Table 440. Rest of South America Drugs of Abuse Testing, by Testing Type USD Million (2021-2026)
  • Table 441. Rest of South America Drugs of Abuse Testing, by Sample Type USD Million (2021-2026)
  • Table 442. Rest of South America Drugs of Abuse Testing, by Analyzers Type USD Million (2021-2026)
  • Table 443. Asia Pacific Drugs of Abuse Testing, by Country USD Million (2021-2026)
  • Table 444. Asia Pacific Drugs of Abuse Testing, by Type USD Million (2021-2026)
  • Table 445. Asia Pacific Drugs of Abuse Testing, by Application USD Million (2021-2026)
  • Table 446. Asia Pacific Drugs of Abuse Testing, by Rapid Testing Device USD Million (2021-2026)
  • Table 447. Asia Pacific Drugs of Abuse Testing, by Testing Type USD Million (2021-2026)
  • Table 448. Asia Pacific Drugs of Abuse Testing, by Sample Type USD Million (2021-2026)
  • Table 449. Asia Pacific Drugs of Abuse Testing, by Analyzers Type USD Million (2021-2026)
  • Table 450. China Drugs of Abuse Testing, by Type USD Million (2021-2026)
  • Table 451. China Drugs of Abuse Testing, by Application USD Million (2021-2026)
  • Table 452. China Drugs of Abuse Testing, by Rapid Testing Device USD Million (2021-2026)
  • Table 453. China Drugs of Abuse Testing, by Testing Type USD Million (2021-2026)
  • Table 454. China Drugs of Abuse Testing, by Sample Type USD Million (2021-2026)
  • Table 455. China Drugs of Abuse Testing, by Analyzers Type USD Million (2021-2026)
  • Table 456. Japan Drugs of Abuse Testing, by Type USD Million (2021-2026)
  • Table 457. Japan Drugs of Abuse Testing, by Application USD Million (2021-2026)
  • Table 458. Japan Drugs of Abuse Testing, by Rapid Testing Device USD Million (2021-2026)
  • Table 459. Japan Drugs of Abuse Testing, by Testing Type USD Million (2021-2026)
  • Table 460. Japan Drugs of Abuse Testing, by Sample Type USD Million (2021-2026)
  • Table 461. Japan Drugs of Abuse Testing, by Analyzers Type USD Million (2021-2026)
  • Table 462. India Drugs of Abuse Testing, by Type USD Million (2021-2026)
  • Table 463. India Drugs of Abuse Testing, by Application USD Million (2021-2026)
  • Table 464. India Drugs of Abuse Testing, by Rapid Testing Device USD Million (2021-2026)
  • Table 465. India Drugs of Abuse Testing, by Testing Type USD Million (2021-2026)
  • Table 466. India Drugs of Abuse Testing, by Sample Type USD Million (2021-2026)
  • Table 467. India Drugs of Abuse Testing, by Analyzers Type USD Million (2021-2026)
  • Table 468. South Korea Drugs of Abuse Testing, by Type USD Million (2021-2026)
  • Table 469. South Korea Drugs of Abuse Testing, by Application USD Million (2021-2026)
  • Table 470. South Korea Drugs of Abuse Testing, by Rapid Testing Device USD Million (2021-2026)
  • Table 471. South Korea Drugs of Abuse Testing, by Testing Type USD Million (2021-2026)
  • Table 472. South Korea Drugs of Abuse Testing, by Sample Type USD Million (2021-2026)
  • Table 473. South Korea Drugs of Abuse Testing, by Analyzers Type USD Million (2021-2026)
  • Table 474. Taiwan Drugs of Abuse Testing, by Type USD Million (2021-2026)
  • Table 475. Taiwan Drugs of Abuse Testing, by Application USD Million (2021-2026)
  • Table 476. Taiwan Drugs of Abuse Testing, by Rapid Testing Device USD Million (2021-2026)
  • Table 477. Taiwan Drugs of Abuse Testing, by Testing Type USD Million (2021-2026)
  • Table 478. Taiwan Drugs of Abuse Testing, by Sample Type USD Million (2021-2026)
  • Table 479. Taiwan Drugs of Abuse Testing, by Analyzers Type USD Million (2021-2026)
  • Table 480. Australia Drugs of Abuse Testing, by Type USD Million (2021-2026)
  • Table 481. Australia Drugs of Abuse Testing, by Application USD Million (2021-2026)
  • Table 482. Australia Drugs of Abuse Testing, by Rapid Testing Device USD Million (2021-2026)
  • Table 483. Australia Drugs of Abuse Testing, by Testing Type USD Million (2021-2026)
  • Table 484. Australia Drugs of Abuse Testing, by Sample Type USD Million (2021-2026)
  • Table 485. Australia Drugs of Abuse Testing, by Analyzers Type USD Million (2021-2026)
  • Table 486. Rest of Asia-Pacific Drugs of Abuse Testing, by Type USD Million (2021-2026)
  • Table 487. Rest of Asia-Pacific Drugs of Abuse Testing, by Application USD Million (2021-2026)
  • Table 488. Rest of Asia-Pacific Drugs of Abuse Testing, by Rapid Testing Device USD Million (2021-2026)
  • Table 489. Rest of Asia-Pacific Drugs of Abuse Testing, by Testing Type USD Million (2021-2026)
  • Table 490. Rest of Asia-Pacific Drugs of Abuse Testing, by Sample Type USD Million (2021-2026)
  • Table 491. Rest of Asia-Pacific Drugs of Abuse Testing, by Analyzers Type USD Million (2021-2026)
  • Table 492. Europe Drugs of Abuse Testing, by Country USD Million (2021-2026)
  • Table 493. Europe Drugs of Abuse Testing, by Type USD Million (2021-2026)
  • Table 494. Europe Drugs of Abuse Testing, by Application USD Million (2021-2026)
  • Table 495. Europe Drugs of Abuse Testing, by Rapid Testing Device USD Million (2021-2026)
  • Table 496. Europe Drugs of Abuse Testing, by Testing Type USD Million (2021-2026)
  • Table 497. Europe Drugs of Abuse Testing, by Sample Type USD Million (2021-2026)
  • Table 498. Europe Drugs of Abuse Testing, by Analyzers Type USD Million (2021-2026)
  • Table 499. Germany Drugs of Abuse Testing, by Type USD Million (2021-2026)
  • Table 500. Germany Drugs of Abuse Testing, by Application USD Million (2021-2026)
  • Table 501. Germany Drugs of Abuse Testing, by Rapid Testing Device USD Million (2021-2026)
  • Table 502. Germany Drugs of Abuse Testing, by Testing Type USD Million (2021-2026)
  • Table 503. Germany Drugs of Abuse Testing, by Sample Type USD Million (2021-2026)
  • Table 504. Germany Drugs of Abuse Testing, by Analyzers Type USD Million (2021-2026)
  • Table 505. France Drugs of Abuse Testing, by Type USD Million (2021-2026)
  • Table 506. France Drugs of Abuse Testing, by Application USD Million (2021-2026)
  • Table 507. France Drugs of Abuse Testing, by Rapid Testing Device USD Million (2021-2026)
  • Table 508. France Drugs of Abuse Testing, by Testing Type USD Million (2021-2026)
  • Table 509. France Drugs of Abuse Testing, by Sample Type USD Million (2021-2026)
  • Table 510. France Drugs of Abuse Testing, by Analyzers Type USD Million (2021-2026)
  • Table 511. Italy Drugs of Abuse Testing, by Type USD Million (2021-2026)
  • Table 512. Italy Drugs of Abuse Testing, by Application USD Million (2021-2026)
  • Table 513. Italy Drugs of Abuse Testing, by Rapid Testing Device USD Million (2021-2026)
  • Table 514. Italy Drugs of Abuse Testing, by Testing Type USD Million (2021-2026)
  • Table 515. Italy Drugs of Abuse Testing, by Sample Type USD Million (2021-2026)
  • Table 516. Italy Drugs of Abuse Testing, by Analyzers Type USD Million (2021-2026)
  • Table 517. United Kingdom Drugs of Abuse Testing, by Type USD Million (2021-2026)
  • Table 518. United Kingdom Drugs of Abuse Testing, by Application USD Million (2021-2026)
  • Table 519. United Kingdom Drugs of Abuse Testing, by Rapid Testing Device USD Million (2021-2026)
  • Table 520. United Kingdom Drugs of Abuse Testing, by Testing Type USD Million (2021-2026)
  • Table 521. United Kingdom Drugs of Abuse Testing, by Sample Type USD Million (2021-2026)
  • Table 522. United Kingdom Drugs of Abuse Testing, by Analyzers Type USD Million (2021-2026)
  • Table 523. Netherlands Drugs of Abuse Testing, by Type USD Million (2021-2026)
  • Table 524. Netherlands Drugs of Abuse Testing, by Application USD Million (2021-2026)
  • Table 525. Netherlands Drugs of Abuse Testing, by Rapid Testing Device USD Million (2021-2026)
  • Table 526. Netherlands Drugs of Abuse Testing, by Testing Type USD Million (2021-2026)
  • Table 527. Netherlands Drugs of Abuse Testing, by Sample Type USD Million (2021-2026)
  • Table 528. Netherlands Drugs of Abuse Testing, by Analyzers Type USD Million (2021-2026)
  • Table 529. Rest of Europe Drugs of Abuse Testing, by Type USD Million (2021-2026)
  • Table 530. Rest of Europe Drugs of Abuse Testing, by Application USD Million (2021-2026)
  • Table 531. Rest of Europe Drugs of Abuse Testing, by Rapid Testing Device USD Million (2021-2026)
  • Table 532. Rest of Europe Drugs of Abuse Testing, by Testing Type USD Million (2021-2026)
  • Table 533. Rest of Europe Drugs of Abuse Testing, by Sample Type USD Million (2021-2026)
  • Table 534. Rest of Europe Drugs of Abuse Testing, by Analyzers Type USD Million (2021-2026)
  • Table 535. MEA Drugs of Abuse Testing, by Country USD Million (2021-2026)
  • Table 536. MEA Drugs of Abuse Testing, by Type USD Million (2021-2026)
  • Table 537. MEA Drugs of Abuse Testing, by Application USD Million (2021-2026)
  • Table 538. MEA Drugs of Abuse Testing, by Rapid Testing Device USD Million (2021-2026)
  • Table 539. MEA Drugs of Abuse Testing, by Testing Type USD Million (2021-2026)
  • Table 540. MEA Drugs of Abuse Testing, by Sample Type USD Million (2021-2026)
  • Table 541. MEA Drugs of Abuse Testing, by Analyzers Type USD Million (2021-2026)
  • Table 542. Middle East Drugs of Abuse Testing, by Type USD Million (2021-2026)
  • Table 543. Middle East Drugs of Abuse Testing, by Application USD Million (2021-2026)
  • Table 544. Middle East Drugs of Abuse Testing, by Rapid Testing Device USD Million (2021-2026)
  • Table 545. Middle East Drugs of Abuse Testing, by Testing Type USD Million (2021-2026)
  • Table 546. Middle East Drugs of Abuse Testing, by Sample Type USD Million (2021-2026)
  • Table 547. Middle East Drugs of Abuse Testing, by Analyzers Type USD Million (2021-2026)
  • Table 548. Africa Drugs of Abuse Testing, by Type USD Million (2021-2026)
  • Table 549. Africa Drugs of Abuse Testing, by Application USD Million (2021-2026)
  • Table 550. Africa Drugs of Abuse Testing, by Rapid Testing Device USD Million (2021-2026)
  • Table 551. Africa Drugs of Abuse Testing, by Testing Type USD Million (2021-2026)
  • Table 552. Africa Drugs of Abuse Testing, by Sample Type USD Million (2021-2026)
  • Table 553. Africa Drugs of Abuse Testing, by Analyzers Type USD Million (2021-2026)
  • Table 554. North America Drugs of Abuse Testing, by Country USD Million (2021-2026)
  • Table 555. North America Drugs of Abuse Testing, by Type USD Million (2021-2026)
  • Table 556. North America Drugs of Abuse Testing, by Application USD Million (2021-2026)
  • Table 557. North America Drugs of Abuse Testing, by Rapid Testing Device USD Million (2021-2026)
  • Table 558. North America Drugs of Abuse Testing, by Testing Type USD Million (2021-2026)
  • Table 559. North America Drugs of Abuse Testing, by Sample Type USD Million (2021-2026)
  • Table 560. North America Drugs of Abuse Testing, by Analyzers Type USD Million (2021-2026)
  • Table 561. United States Drugs of Abuse Testing, by Type USD Million (2021-2026)
  • Table 562. United States Drugs of Abuse Testing, by Application USD Million (2021-2026)
  • Table 563. United States Drugs of Abuse Testing, by Rapid Testing Device USD Million (2021-2026)
  • Table 564. United States Drugs of Abuse Testing, by Testing Type USD Million (2021-2026)
  • Table 565. United States Drugs of Abuse Testing, by Sample Type USD Million (2021-2026)
  • Table 566. United States Drugs of Abuse Testing, by Analyzers Type USD Million (2021-2026)
  • Table 567. Canada Drugs of Abuse Testing, by Type USD Million (2021-2026)
  • Table 568. Canada Drugs of Abuse Testing, by Application USD Million (2021-2026)
  • Table 569. Canada Drugs of Abuse Testing, by Rapid Testing Device USD Million (2021-2026)
  • Table 570. Canada Drugs of Abuse Testing, by Testing Type USD Million (2021-2026)
  • Table 571. Canada Drugs of Abuse Testing, by Sample Type USD Million (2021-2026)
  • Table 572. Canada Drugs of Abuse Testing, by Analyzers Type USD Million (2021-2026)
  • Table 573. Mexico Drugs of Abuse Testing, by Type USD Million (2021-2026)
  • Table 574. Mexico Drugs of Abuse Testing, by Application USD Million (2021-2026)
  • Table 575. Mexico Drugs of Abuse Testing, by Rapid Testing Device USD Million (2021-2026)
  • Table 576. Mexico Drugs of Abuse Testing, by Testing Type USD Million (2021-2026)
  • Table 577. Mexico Drugs of Abuse Testing, by Sample Type USD Million (2021-2026)
  • Table 578. Mexico Drugs of Abuse Testing, by Analyzers Type USD Million (2021-2026)
  • Table 579. Drugs of Abuse Testing Sales: by Type(Unit)
  • Table 580. Drugs of Abuse Testing Sales Psychostimulants , by Region Unit (2021-2026)
  • Table 581. Drugs of Abuse Testing Sales Narcotic , by Region Unit (2021-2026)
  • Table 582. Drugs of Abuse Testing Sales Hallucinogens , by Region Unit (2021-2026)
  • Table 583. Drugs of Abuse Testing Sales Sedatives , by Region Unit (2021-2026)
  • Table 584. Drugs of Abuse Testing Sales Others , by Region Unit (2021-2026)
  • Table 585. Drugs of Abuse Testing Sales: by Application(Unit)
  • Table 586. Drugs of Abuse Testing Sales Hospitals , by Region Unit (2021-2026)
  • Table 587. Drugs of Abuse Testing Sales Diagnostics Laboratories , by Region Unit (2021-2026)
  • Table 588. Drugs of Abuse Testing Sales Forensic Laboratories , by Region Unit (2021-2026)
  • Table 589. Drugs of Abuse Testing Sales Others , by Region Unit (2021-2026)
  • Table 590. Drugs of Abuse Testing Sales: by Rapid Testing Device(Unit)
  • Table 591. Drugs of Abuse Testing Sales Urine Testing , by Region Unit (2021-2026)
  • Table 592. Drugs of Abuse Testing Sales Oral Fluid Testing , by Region Unit (2021-2026)
  • Table 593. Drugs of Abuse Testing Sales: by Testing Type(Unit)
  • Table 594. Drugs of Abuse Testing Sales Pain Management Testing , by Region Unit (2021-2026)
  • Table 595. Drugs of Abuse Testing Sales Criminal Justice Testing , by Region Unit (2021-2026)
  • Table 596. Drugs of Abuse Testing Sales Work Place Screening , by Region Unit (2021-2026)
  • Table 597. Drugs of Abuse Testing Sales: by Sample Type(Unit)
  • Table 598. Drugs of Abuse Testing Sales Saliva , by Region Unit (2021-2026)
  • Table 599. Drugs of Abuse Testing Sales Breath , by Region Unit (2021-2026)
  • Table 600. Drugs of Abuse Testing Sales Urine , by Region Unit (2021-2026)
  • Table 601. Drugs of Abuse Testing Sales Blood , by Region Unit (2021-2026)
  • Table 602. Drugs of Abuse Testing Sales Hair and Sweat , by Region Unit (2021-2026)
  • Table 603. Drugs of Abuse Testing Sales: by Analyzers Type(Unit)
  • Table 604. Drugs of Abuse Testing Sales Immunoassays , by Region Unit (2021-2026)
  • Table 605. Drugs of Abuse Testing Sales Chromatographic Devices , by Region Unit (2021-2026)
  • Table 606. Drugs of Abuse Testing Sales Breath Analyzers , by Region Unit (2021-2026)
  • Table 607. South America Drugs of Abuse Testing Sales, by Country Unit (2021-2026)
  • Table 608. South America Drugs of Abuse Testing Sales, by Type Unit (2021-2026)
  • Table 609. South America Drugs of Abuse Testing Sales, by Application Unit (2021-2026)
  • Table 610. South America Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2021-2026)
  • Table 611. South America Drugs of Abuse Testing Sales, by Testing Type Unit (2021-2026)
  • Table 612. South America Drugs of Abuse Testing Sales, by Sample Type Unit (2021-2026)
  • Table 613. South America Drugs of Abuse Testing Sales, by Analyzers Type Unit (2021-2026)
  • Table 614. Brazil Drugs of Abuse Testing Sales, by Type Unit (2021-2026)
  • Table 615. Brazil Drugs of Abuse Testing Sales, by Application Unit (2021-2026)
  • Table 616. Brazil Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2021-2026)
  • Table 617. Brazil Drugs of Abuse Testing Sales, by Testing Type Unit (2021-2026)
  • Table 618. Brazil Drugs of Abuse Testing Sales, by Sample Type Unit (2021-2026)
  • Table 619. Brazil Drugs of Abuse Testing Sales, by Analyzers Type Unit (2021-2026)
  • Table 620. Argentina Drugs of Abuse Testing Sales, by Type Unit (2021-2026)
  • Table 621. Argentina Drugs of Abuse Testing Sales, by Application Unit (2021-2026)
  • Table 622. Argentina Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2021-2026)
  • Table 623. Argentina Drugs of Abuse Testing Sales, by Testing Type Unit (2021-2026)
  • Table 624. Argentina Drugs of Abuse Testing Sales, by Sample Type Unit (2021-2026)
  • Table 625. Argentina Drugs of Abuse Testing Sales, by Analyzers Type Unit (2021-2026)
  • Table 626. Rest of South America Drugs of Abuse Testing Sales, by Type Unit (2021-2026)
  • Table 627. Rest of South America Drugs of Abuse Testing Sales, by Application Unit (2021-2026)
  • Table 628. Rest of South America Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2021-2026)
  • Table 629. Rest of South America Drugs of Abuse Testing Sales, by Testing Type Unit (2021-2026)
  • Table 630. Rest of South America Drugs of Abuse Testing Sales, by Sample Type Unit (2021-2026)
  • Table 631. Rest of South America Drugs of Abuse Testing Sales, by Analyzers Type Unit (2021-2026)
  • Table 632. Asia Pacific Drugs of Abuse Testing Sales, by Country Unit (2021-2026)
  • Table 633. Asia Pacific Drugs of Abuse Testing Sales, by Type Unit (2021-2026)
  • Table 634. Asia Pacific Drugs of Abuse Testing Sales, by Application Unit (2021-2026)
  • Table 635. Asia Pacific Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2021-2026)
  • Table 636. Asia Pacific Drugs of Abuse Testing Sales, by Testing Type Unit (2021-2026)
  • Table 637. Asia Pacific Drugs of Abuse Testing Sales, by Sample Type Unit (2021-2026)
  • Table 638. Asia Pacific Drugs of Abuse Testing Sales, by Analyzers Type Unit (2021-2026)
  • Table 639. China Drugs of Abuse Testing Sales, by Type Unit (2021-2026)
  • Table 640. China Drugs of Abuse Testing Sales, by Application Unit (2021-2026)
  • Table 641. China Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2021-2026)
  • Table 642. China Drugs of Abuse Testing Sales, by Testing Type Unit (2021-2026)
  • Table 643. China Drugs of Abuse Testing Sales, by Sample Type Unit (2021-2026)
  • Table 644. China Drugs of Abuse Testing Sales, by Analyzers Type Unit (2021-2026)
  • Table 645. Japan Drugs of Abuse Testing Sales, by Type Unit (2021-2026)
  • Table 646. Japan Drugs of Abuse Testing Sales, by Application Unit (2021-2026)
  • Table 647. Japan Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2021-2026)
  • Table 648. Japan Drugs of Abuse Testing Sales, by Testing Type Unit (2021-2026)
  • Table 649. Japan Drugs of Abuse Testing Sales, by Sample Type Unit (2021-2026)
  • Table 650. Japan Drugs of Abuse Testing Sales, by Analyzers Type Unit (2021-2026)
  • Table 651. India Drugs of Abuse Testing Sales, by Type Unit (2021-2026)
  • Table 652. India Drugs of Abuse Testing Sales, by Application Unit (2021-2026)
  • Table 653. India Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2021-2026)
  • Table 654. India Drugs of Abuse Testing Sales, by Testing Type Unit (2021-2026)
  • Table 655. India Drugs of Abuse Testing Sales, by Sample Type Unit (2021-2026)
  • Table 656. India Drugs of Abuse Testing Sales, by Analyzers Type Unit (2021-2026)
  • Table 657. South Korea Drugs of Abuse Testing Sales, by Type Unit (2021-2026)
  • Table 658. South Korea Drugs of Abuse Testing Sales, by Application Unit (2021-2026)
  • Table 659. South Korea Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2021-2026)
  • Table 660. South Korea Drugs of Abuse Testing Sales, by Testing Type Unit (2021-2026)
  • Table 661. South Korea Drugs of Abuse Testing Sales, by Sample Type Unit (2021-2026)
  • Table 662. South Korea Drugs of Abuse Testing Sales, by Analyzers Type Unit (2021-2026)
  • Table 663. Taiwan Drugs of Abuse Testing Sales, by Type Unit (2021-2026)
  • Table 664. Taiwan Drugs of Abuse Testing Sales, by Application Unit (2021-2026)
  • Table 665. Taiwan Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2021-2026)
  • Table 666. Taiwan Drugs of Abuse Testing Sales, by Testing Type Unit (2021-2026)
  • Table 667. Taiwan Drugs of Abuse Testing Sales, by Sample Type Unit (2021-2026)
  • Table 668. Taiwan Drugs of Abuse Testing Sales, by Analyzers Type Unit (2021-2026)
  • Table 669. Australia Drugs of Abuse Testing Sales, by Type Unit (2021-2026)
  • Table 670. Australia Drugs of Abuse Testing Sales, by Application Unit (2021-2026)
  • Table 671. Australia Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2021-2026)
  • Table 672. Australia Drugs of Abuse Testing Sales, by Testing Type Unit (2021-2026)
  • Table 673. Australia Drugs of Abuse Testing Sales, by Sample Type Unit (2021-2026)
  • Table 674. Australia Drugs of Abuse Testing Sales, by Analyzers Type Unit (2021-2026)
  • Table 675. Rest of Asia-Pacific Drugs of Abuse Testing Sales, by Type Unit (2021-2026)
  • Table 676. Rest of Asia-Pacific Drugs of Abuse Testing Sales, by Application Unit (2021-2026)
  • Table 677. Rest of Asia-Pacific Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2021-2026)
  • Table 678. Rest of Asia-Pacific Drugs of Abuse Testing Sales, by Testing Type Unit (2021-2026)
  • Table 679. Rest of Asia-Pacific Drugs of Abuse Testing Sales, by Sample Type Unit (2021-2026)
  • Table 680. Rest of Asia-Pacific Drugs of Abuse Testing Sales, by Analyzers Type Unit (2021-2026)
  • Table 681. Europe Drugs of Abuse Testing Sales, by Country Unit (2021-2026)
  • Table 682. Europe Drugs of Abuse Testing Sales, by Type Unit (2021-2026)
  • Table 683. Europe Drugs of Abuse Testing Sales, by Application Unit (2021-2026)
  • Table 684. Europe Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2021-2026)
  • Table 685. Europe Drugs of Abuse Testing Sales, by Testing Type Unit (2021-2026)
  • Table 686. Europe Drugs of Abuse Testing Sales, by Sample Type Unit (2021-2026)
  • Table 687. Europe Drugs of Abuse Testing Sales, by Analyzers Type Unit (2021-2026)
  • Table 688. Germany Drugs of Abuse Testing Sales, by Type Unit (2021-2026)
  • Table 689. Germany Drugs of Abuse Testing Sales, by Application Unit (2021-2026)
  • Table 690. Germany Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2021-2026)
  • Table 691. Germany Drugs of Abuse Testing Sales, by Testing Type Unit (2021-2026)
  • Table 692. Germany Drugs of Abuse Testing Sales, by Sample Type Unit (2021-2026)
  • Table 693. Germany Drugs of Abuse Testing Sales, by Analyzers Type Unit (2021-2026)
  • Table 694. France Drugs of Abuse Testing Sales, by Type Unit (2021-2026)
  • Table 695. France Drugs of Abuse Testing Sales, by Application Unit (2021-2026)
  • Table 696. France Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2021-2026)
  • Table 697. France Drugs of Abuse Testing Sales, by Testing Type Unit (2021-2026)
  • Table 698. France Drugs of Abuse Testing Sales, by Sample Type Unit (2021-2026)
  • Table 699. France Drugs of Abuse Testing Sales, by Analyzers Type Unit (2021-2026)
  • Table 700. Italy Drugs of Abuse Testing Sales, by Type Unit (2021-2026)
  • Table 701. Italy Drugs of Abuse Testing Sales, by Application Unit (2021-2026)
  • Table 702. Italy Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2021-2026)
  • Table 703. Italy Drugs of Abuse Testing Sales, by Testing Type Unit (2021-2026)
  • Table 704. Italy Drugs of Abuse Testing Sales, by Sample Type Unit (2021-2026)
  • Table 705. Italy Drugs of Abuse Testing Sales, by Analyzers Type Unit (2021-2026)
  • Table 706. United Kingdom Drugs of Abuse Testing Sales, by Type Unit (2021-2026)
  • Table 707. United Kingdom Drugs of Abuse Testing Sales, by Application Unit (2021-2026)
  • Table 708. United Kingdom Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2021-2026)
  • Table 709. United Kingdom Drugs of Abuse Testing Sales, by Testing Type Unit (2021-2026)
  • Table 710. United Kingdom Drugs of Abuse Testing Sales, by Sample Type Unit (2021-2026)
  • Table 711. United Kingdom Drugs of Abuse Testing Sales, by Analyzers Type Unit (2021-2026)
  • Table 712. Netherlands Drugs of Abuse Testing Sales, by Type Unit (2021-2026)
  • Table 713. Netherlands Drugs of Abuse Testing Sales, by Application Unit (2021-2026)
  • Table 714. Netherlands Drugs of Abuse Testing Sales, by Rapid Testing Device Unit (2021-2026)
  • Table 715. Netherlands Drugs of Abuse Testing Sales, by Testing Type Unit (2021-2026)
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Drugs of Abuse Testing: by Type USD Million (2015-2020)
  • Figure 5. Global Drugs of Abuse Testing: by Application USD Million (2015-2020)
  • Figure 6. Global Drugs of Abuse Testing: by Rapid Testing Device USD Million (2015-2020)
  • Figure 7. Global Drugs of Abuse Testing: by Testing Type USD Million (2015-2020)
  • Figure 8. Global Drugs of Abuse Testing: by Sample Type USD Million (2015-2020)
  • Figure 9. Global Drugs of Abuse Testing: by Analyzers Type USD Million (2015-2020)
  • Figure 10. South America Drugs of Abuse Testing Share (%), by Country
  • Figure 11. Asia Pacific Drugs of Abuse Testing Share (%), by Country
  • Figure 12. Europe Drugs of Abuse Testing Share (%), by Country
  • Figure 13. MEA Drugs of Abuse Testing Share (%), by Country
  • Figure 14. North America Drugs of Abuse Testing Share (%), by Country
  • Figure 15. Global Drugs of Abuse Testing: by Type Unit (2015-2020)
  • Figure 16. Global Drugs of Abuse Testing: by Application Unit (2015-2020)
  • Figure 17. Global Drugs of Abuse Testing: by Rapid Testing Device Unit (2015-2020)
  • Figure 18. Global Drugs of Abuse Testing: by Testing Type Unit (2015-2020)
  • Figure 19. Global Drugs of Abuse Testing: by Sample Type Unit (2015-2020)
  • Figure 20. Global Drugs of Abuse Testing: by Analyzers Type Unit (2015-2020)
  • Figure 21. South America Drugs of Abuse Testing Share (%), by Country
  • Figure 22. Asia Pacific Drugs of Abuse Testing Share (%), by Country
  • Figure 23. Europe Drugs of Abuse Testing Share (%), by Country
  • Figure 24. MEA Drugs of Abuse Testing Share (%), by Country
  • Figure 25. North America Drugs of Abuse Testing Share (%), by Country
  • Figure 26. Global Drugs of Abuse Testing: by Type USD/Units (2015-2020)
  • Figure 27. Global Drugs of Abuse Testing share by Players 2020 (%)
  • Figure 28. Global Drugs of Abuse Testing share by Players (Top 3) 2020(%)
  • Figure 29. Global Drugs of Abuse Testing share by Players (Top 5) 2020(%)
  • Figure 30. BCG Matrix for key Companies
  • Figure 31. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2020
  • Figure 33. Thermo Fisher Scientific Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Thermo Fisher Scientific Inc. (United States) Revenue: by Geography 2020
  • Figure 35. Drägerwerk AG & Co. KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Drägerwerk AG & Co. KGaA (Germany) Revenue: by Geography 2020
  • Figure 37. Laboratory Corporation of America Holdings (United States) Revenue, Net Income and Gross profit
  • Figure 38. Laboratory Corporation of America Holdings (United States) Revenue: by Geography 2020
  • Figure 39. Siemens Healthineers (Germany) Revenue, Net Income and Gross profit
  • Figure 40. Siemens Healthineers (Germany) Revenue: by Geography 2020
  • Figure 41. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 42. Abbott Laboratories (United States) Revenue: by Geography 2020
  • Figure 43. Danaher Corporation (Beckman Coulter, Inc.) (United States) Revenue, Net Income and Gross profit
  • Figure 44. Danaher Corporation (Beckman Coulter, Inc.) (United States) Revenue: by Geography 2020
  • Figure 45. Express Diagnostics International Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 46. Express Diagnostics International Inc. (United States) Revenue: by Geography 2020
  • Figure 47. Shimadzu Corporation. (Japan) Revenue, Net Income and Gross profit
  • Figure 48. Shimadzu Corporation. (Japan) Revenue: by Geography 2020
  • Figure 49. Quest Diagnostics (United States) Revenue, Net Income and Gross profit
  • Figure 50. Quest Diagnostics (United States) Revenue: by Geography 2020
  • Figure 51. Global Drugs of Abuse Testing: by Type USD Million (2021-2026)
  • Figure 52. Global Drugs of Abuse Testing: by Application USD Million (2021-2026)
  • Figure 53. Global Drugs of Abuse Testing: by Rapid Testing Device USD Million (2021-2026)
  • Figure 54. Global Drugs of Abuse Testing: by Testing Type USD Million (2021-2026)
  • Figure 55. Global Drugs of Abuse Testing: by Sample Type USD Million (2021-2026)
  • Figure 56. Global Drugs of Abuse Testing: by Analyzers Type USD Million (2021-2026)
  • Figure 57. South America Drugs of Abuse Testing Share (%), by Country
  • Figure 58. Asia Pacific Drugs of Abuse Testing Share (%), by Country
  • Figure 59. Europe Drugs of Abuse Testing Share (%), by Country
  • Figure 60. MEA Drugs of Abuse Testing Share (%), by Country
  • Figure 61. North America Drugs of Abuse Testing Share (%), by Country
  • Figure 62. Global Drugs of Abuse Testing: by Type Unit (2021-2026)
  • Figure 63. Global Drugs of Abuse Testing: by Application Unit (2021-2026)
  • Figure 64. Global Drugs of Abuse Testing: by Rapid Testing Device Unit (2021-2026)
  • Figure 65. Global Drugs of Abuse Testing: by Testing Type Unit (2021-2026)
  • Figure 66. Global Drugs of Abuse Testing: by Sample Type Unit (2021-2026)
  • Figure 67. Global Drugs of Abuse Testing: by Analyzers Type Unit (2021-2026)
  • Figure 68. South America Drugs of Abuse Testing Share (%), by Country
  • Figure 69. Asia Pacific Drugs of Abuse Testing Share (%), by Country
  • Figure 70. Europe Drugs of Abuse Testing Share (%), by Country
  • Figure 71. MEA Drugs of Abuse Testing Share (%), by Country
  • Figure 72. North America Drugs of Abuse Testing Share (%), by Country
  • Figure 73. Global Drugs of Abuse Testing: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Thermo Fisher Scientific Inc. (United States)
  • Drägerwerk AG & Co. KGaA (Germany)
  • Laboratory Corporation of America Holdings (United States)
  • Siemens Healthineers (Germany)
  • Abbott Laboratories (United States)
  • Danaher Corporation (Beckman Coulter, Inc.) (United States)
  • Express Diagnostics International Inc. (United States)
  • Shimadzu Corporation. (Japan)
  • Quest Diagnostics (United States)
Additional players considered in the study are as follows:
Psychemedics Corporation (United States) , Bio-Rad Laboratories, Inc (United States) , Sonic Healthcare (Australia)
Select User Access Type

Key Highlights of Report


Jan 2024 245 Pages 59 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Drugs of Abuse Testing Quantitative research analysis
Global Drugs of Abuse Testing Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Global Drugs of Abuse Testing market is expected to see a growth of % during projected year 2020 to 2026.
The prominent players of Global Drugs of Abuse Testing market are F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (United States), Drägerwerk AG & Co. KGaA (Germany), Laboratory Corporation of America Holdings (United States), Siemens Healthineers (Germany), Abbott Laboratories (United States), Danaher Corporation (Beckman Coulter, Inc.) (United States), Express Diagnostics International Inc. (United States), Shimadzu Corporation. (Japan) and Quest Diagnostics (United States), to name a few.
In this highly competitive & fast evolving Drugs of Abuse Testing industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.

Know More About Global Drugs of Abuse Testing Report?

Have a Query? Click Here

Other Related Reports

mHealth Services Comprehensive Study by Type (Wellness Service, Prevention, Monitoring Service, Diagnostic Service, Treatment, Information and reference), Application (General Healthcare and Fitness,...
$ 3750
Emergency Ambulance Comprehensive Study by Type (SUV Emergency Ambulance, Truck Emergency Ambulance, Bus Emergency Ambulance, Others), Application (Hospital, Emergency Center, Others), Services (Emer...
$ 3450
Ambulatory Electronic Health Record Comprehensive Study by Type (Practice Management, Patient Management, E-prescribing, Referral Management, Population Health Management, Decision Support, Health An...
$ 3750
Clinical Trials Comprehensive Study by Type (Interventional, Observational, Expanded Access), Application (Autoimmune/Inflammation, Pain Management, Oncology, Cardiovascular, Central Nervous System (...
$ 3750
Spine Biologics Comprehensive Study by Type (Bone Graft Substitutes (Synthetic Bone Grafts, Demineralized Bone Matrix (DBM), Bone Morphogenetic Proteins (BMP)), Bone Allografts (Machined Bone Allogra...
$ 3750
Skilled Nursing Care Services Comprehensive Study by Type (Home Care, Residential Care, Acute Care), Application (Old Age People, Children), Connectivity (Connected To Hospital, Connected To Assisted...
$ 3650